Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
21 June 2023 - 6:46AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE
ISSUER
PURSUANT TO RULE 13a-16
OR 15d-16 OF THE
SECURITIES EXCHANGE ACT
OF 1934
For the month of June 2023
Commission File Number: 001-39446
CureVac N.V.
(Exact Name of Registrant as Specified in Its
Charter)
Friedrich-Miescher-Strasse 15, 72076
Tübingen, Germany
+49 7071 9883 0
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:
On June 20, 2023, CureVac N.V. (the “Company”) issued a
press release announcing that the first participant was dosed with its investigational cancer vaccine CVGBM in a Phase 1 study. A first
data readout is expected in the second half of 2024.
The information included in this Form 6-K (including Exhibit 99.1,
but excluding the statements of the Company’s Chief Development Officer contained in Exhibit 99.1 hereto) is hereby incorporated
by reference into the Company’s Registration Statement on Form F-3 (File No. 333-259613).
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
CUREVAC N.V. |
| |
|
|
| |
By: |
/s/ Alexander Zehnder |
| |
|
Chief Executive Officer |
Date: June 20, 2023
EXHIBIT INDEX
CureVac NV (NASDAQ:CVAC)
Historical Stock Chart
From May 2024 to Jun 2024
CureVac NV (NASDAQ:CVAC)
Historical Stock Chart
From Jun 2023 to Jun 2024
